Filing Details

Accession Number:
0001177648-19-000013
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-13 21:28:37
Reporting Period:
2019-02-12
Accepted Time:
2019-02-13 21:28:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1177648 Enanta Pharmaceuticals Inc ENTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1607643 S. Nathaniel Gardiner C/O Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown MA 02472
Sr. Vp & General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-12 4,000 $0.00 21,827 No 4 A Direct
Common Stock Acquisiton 2019-02-12 10,000 $0.00 31,827 No 4 A Direct
Common Stock Disposition 2019-02-12 4,579 $88.88 27,248 No 4 F Direct
Common Stock Disposition 2019-02-13 3,270 $95.28 23,978 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 F Direct
No 4 S Direct
Footnotes
  1. Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on January 4, 2017 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2019.
  2. Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on January 4, 2017 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2019.
  3. Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
  4. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018.
  5. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.76, inclusive.